-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $8 Price Target

Benzinga·11/12/2026 13:17:06
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $8 price target.